Published in Ann Oncol on December 12, 2012
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol (2014) 1.26
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer (2016) 0.77
Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis. Int J Clin Exp Med (2015) 0.76
Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croat Med J (2017) 0.75
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol (2015) 0.75
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol (2015) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2005) 7.03
Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut (2000) 4.32
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 2.71
LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet (1993) 2.49
Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood (2000) 2.39
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol (1997) 2.38
CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood (1996) 2.30
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol (2000) 2.30
Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol (2003) 2.28
Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23
Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol (2005) 2.20
Hypodiploidy is a major prognostic factor in multiple myeloma. Blood (2001) 2.17
Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med (1999) 2.13
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol (2011) 2.12
Extranodal Hodgkin disease: spectrum of disease. Radiographics (2001) 1.99
A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med (1995) 1.94
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol (1991) 1.94
CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol (1990) 1.93
Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol (1997) 1.86
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol (2001) 1.85
Is sclerosing angiomatoid nodular transformation (SANT) of the splenic red pulp identical to inflammatory pseudotumour? Report of 16 cases. Histopathology (2008) 1.82
Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood (1990) 1.81
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol (2000) 1.77
Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol (1997) 1.77
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol (1999) 1.76
Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol (2007) 1.75
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol (2006) 1.74
The health of caregivers for children with disabilities: caregiver perspectives. Child Care Health Dev (2007) 1.73
Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood (1993) 1.71
Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab (2002) 1.70
Deficits of cognitive executive functions in patients with sleep apnea syndrome. Sleep (1995) 1.66
Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood (1998) 1.65
European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL) Ann Oncol (1994) 1.65
A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother (1994) 1.64
Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut (1985) 1.64
Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma. Blood (1992) 1.59
Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol (2004) 1.59
PTEN gene alterations in lymphoid neoplasms. Blood (1998) 1.57
Cloning of a breakpoint cluster region at band 3q27 involved in human non-Hodgkin's lymphoma. Genes Chromosomes Cancer (1993) 1.56
Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center. Blood (1999) 1.51
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia (2007) 1.51
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol (2013) 1.51
Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst (2000) 1.51
Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia (1998) 1.49
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol (2008) 1.49
Hematobilia resulting from heterotopic stomach in the gallbladder neck. Surgery (1989) 1.48
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood (1994) 1.48
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood (1996) 1.47
Thymoma-associated pancytopenia: effectiveness of cyclosporine A. Ann Hematol (1998) 1.47
Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood (1994) 1.46
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant (2000) 1.44
antiphospholipid antibodies and RA: presence of beta2GP1 independent aCL. Ann Rheum Dis (2001) 1.44
HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors. Ann Oncol (1991) 1.44
Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. Am J Hematol (1996) 1.42
A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J Clin Oncol (1991) 1.42
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia (2012) 1.42
Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int (2006) 1.40
Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol (2003) 1.40
How should prognostic factors influence therapy in follicular lymphomas? Ann Oncol (1991) 1.39
[High fetal irradiation: about one pregnant woman receiving infradiaphragmatic radiotherapy for Hodgkin lymphoma]. Cancer Radiother (2007) 1.39
Occurrence of T-cell lymphoma in a patient with acute myelogenous leukemia. Ann Hematol (1996) 1.39
Neurologic manifestations of essential thrombocythemia. Ann Intern Med (1983) 1.39
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia (2009) 1.38
Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial. HIV Med (2013) 1.38
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia (2008) 1.37
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37